Doylestown, PA (February 1, 2016) – 1 out of 3 Americans admits to being nervous about seeing the dentist and nearly half consider dental visits a “necessary evil,” according to the results of an online survey published today. Conducted by Harris Poll on behalf of OPT-In Dental Advantage, the nation’s first branded private practice organization dedicated to patient advocacy, the survey found that misconceptions about dental visits persist among a significant portion of Americans.
“Despite considerable advancements in preventative care and technology, making dentistry easier and more comfortable than ever before, patients still have real concerns about dental visits,” said OPT-In Dental Advantage Founder and President, Dr. Dean Mersky. “We as dentists have a responsibility to address those concerns. We need to bridge the gap between truth and fiction to create trust between dentists and patients. That’s why OPT-In is launching a dental education campaign, Speaking The Tooth, focused on dispelling patients’ fears by sharing free and accessible information about everything from the reality of how dental insurance works to what to ask your dentist at every check-up.”
The survey of more than 2,000 adults released today also revealed that older patients tend to have more negative perceptions of dental visits than their younger counterparts, and nearly 1 in 5 of those polled lacks certainty about their personal dental health.
“We want to address the factors that are preventing patients from feeling confident and comfortable in their interactions with their dentists,” Dr. Mersky explained. “Sharing quality information about the true in’s-and-out’s of oral health will open communication channels and help make patient-dentist relationships what they should be. It’s time to take the worry and mystery out of a dental visit and make the experience one that builds confidence instead.”
In support of the aim of empowering patients through access to dental information, Speaking The Tooth materials are now available on the OPT-In website http://www.optindentaladvantage.com/blog.
The UConn School of Dental Medicine has been named winner of the 2016 William J. Gies Award for Outstanding Achievement by an Academic Dental Institution. The Gies Awards are considered to be among the preeminent awards in the field of dental education.
“We are truly honored to be the recipient of this prestigious, national award,” said Dr. R.L. Monty MacNeil, dean of the UConn School of Dental Medicine. “It is a cooperative achievement, and all faculty, trainees, and graduates of the program since its inception have made significant contributions and should share in our pride. The award extends beyond the dental school and includes the Graduate School and our valued faculty colleagues in the School of Medicine.”
The School of Dental Medicine is home to more than 70-full time faculty, 110 staff, and 167 dental students. Founded in 1968, it has issued 1,585 dental medical degrees since its first graduating class of 1972. The School offers a full-range of clinical dental services and last year, provided care for nearly 75,000 dental patients.
The Gies Award for Outstanding Achievement by an Academic Dental Institution recognizes worthy and socially commendable actions that make a substantial contribution to oral health and dental education. The accomplishments of UConn’s Skeletal Biology and Regeneration Program were highlighted in the nomination.
The Skeletal Biology and Regeneration Program, one of the seven areas of concentration in the Biomedical Science Ph.D. Program at UConn Health, is highly multidisciplinary and collaborates with basic science departments and centers across the Schools of Medicine and Dental Medicine.
Formerly known as the Skeletal Craniofacial and Oral Biology Program, it was developed in 1980 and was one of the first programs established in the United States dedicated to advancing academic dentistry by educating and preparing outstanding and dedicated leaders in dental education.
“The UConn School of Dental Medicine was considered a pioneer at the time for introducing the DMD/Ph.D. training track,” says Dr. Mina Mina, professor and chair of the Division of Pediatric Dentistry, Department of Craniofacial Sciences, and a graduate of the program. “Our alumni have made an impact on the academic world by becoming successful researchers and educators not only in dental institutions but also in medical and graduate schools.”
Dr. Caroline Dealy, director of the Skeletal Biology and Regeneration Graduate Program, says, “The program has made a tremendous impact on training academic dentists and continues to educate the next generation of scientific scholars and health care practitioners.
The Gies Award will be presented to UConn on March 14 at the ADEA’s Annual Session and Exhibition in Denver, Colorado.
Source: UConn|Health Information Officer
Ivoclar has announced its All Digital All Options Showcase. Antendees can learn how investments in digital technology can add value to their laboratory's unique business model. Presentations will cover the latest in 3Shape scanner capabilities, Zenotec milling machines, and innovations in Ivoclar Vivadent materials. Spend time with the 3Shape and Ivoclar Vivadent teams to learn more about integration of the latest technology into your laboratory.
The cost to attend is $49 which includes lunch, presentations, demonstrations, and special promotions.
Dates and Locations:
March 11 - Universal City, California: Sheraton Universal Hotel Univeral City
March 18 - Kansas City, Missouri: Hilton Kansas City Airport
May 20 - New York, New York: New York LaGuardia Airport Marriott
June 3 - Denver, Colorado: Denver Marriott Tech Center
August 19 - Cincinnati, Ohio: Renaissance Cincinnati Downtown
September 23 - Ft. Lauderdale, Florida: Hollywood Beach Marriott
11:45am - 12:30pm: Registration + Lunch
12:30 pm - 2:00pm: Technology updates by product specialists
2:00pm - 4:00pm: Live technical demonstrations
4 CE Hours
IDT wants to hear from you about occlusion. Please answer the following questions and email to email@example.com to help an IDT board member address the subject in an upcoming MasterClass article.
, /PRNewswire/ -- For the fourth year in a row, Colgate-Palmolive Company ("Colgate"), as part of its Bright Smiles, Bright Futures™ program, and Family Dollar have partnered to inspire African-American families during February's Black History Month to honor their past and treasure their future by paying close attention to overall health and oral hygiene.
February is a special month where the nation acknowledges the strides made in the African-American community. But there's still more to go in the area of oral health care — currently, approximately one-third of African-American adults live with untreated dental caries. Without proper treatment, tooth decay can progress and eventually result in a cavity or even tooth loss. It's important that parents teach their children about adopting healthy dental habits at an early age, and Colgate and Family Dollar are committed to providing education and improving oral hygiene in families across the U.S. As such, Colgate will be offering exclusive in-store promotions on Colgate® toothpastes, toothbrushes and mouthwash products during .
"Colgate is thrilled to continue the longstanding partnership with Family Dollar in celebrating Black History Month," says, general manager of multicultural marketing, Colgate-Palmolive. "We share the common goal of empowering African-Americans and all families to be their best selves by taking charge of their dental and overall health and are proud to bring this program to multiple cities across the U.S. for the fourth year in a row "
The Colgate Bright Smiles, Bright Futures® mobile dental van, which reaches more than 1,000 towns and more than 10 million American children each year, will visit 22 select Family Dollar locations in, , , and this month to provide complimentary dental screenings, wellness packs, and treatment referrals for children ages 3-12. In addition, there will be oral care tips and educational information on hand for the entire family.
St. Louis, February 10, 2016 — Young children (ages 6-10) with severely protruded upper front teeth, commonly called “buck teeth,” are at increased risk for dental trauma and may benefit from an orthodontic correction, according to a study published recently in the American Journal of Orthodontics & Dentofacial Orthopedics*. The study found that approximately 1 in 3 children who were treated for severely protruding teeth were less likely to experience dental trauma (such as a chipped, broken or knocked out permanent tooth).
“Active children who play organized sports or love the playground and who have severely protruding teeth may benefit from early intervention by an orthodontist,” says Morris N. Poole, DDS, president of the American Association of Orthodontists (AAO).
“Youngsters with protruding teeth don’t have adequate lip coverage to protect their teeth from a blow or a fall. The result of losing or damaging a front tooth in childhood becomes a lifelong problem. We only get one set of permanent teeth, and the corrective measures to restore or replace a broken or lost tooth can be expensive, and likely will need to be repeated over the course of a lifetime.”
According to the study, protruding teeth occur in about 15% of children ages 12-15 in the U.S. and is one of the most common problems treated by orthodontists. Early intervention (before adolescence) is warranted in some cases, say the study’s authors. The AAO recommends that all children get a check-up with an orthodontist no later than age 7. If a check-up reveals a child will need orthodontic treatment at some point, the orthodontist will be able to recommend the most appropriate treatment at the most appropriate time.
“Protruding front teeth cause other problems for children. The ‘bite’ – the manner in which the upper and lower teeth meet – may be improper, and make it difficult for a child to bite food or to chew properly. The condition can interfere with speech for some individuals. And there’s an emotional toll, too, for children who may be bullied because of their teeth,” says Dr. Poole. “Interceptive treatment addresses the immediate protrusion problem. Parents need to know that most patients will require a second phase of treatment after most or all of their permanent teeth are in to move teeth into their final, optimal positions.”
“Parents should also understand that children go through what we call an ‘ugly duckling’ phase, when permanent teeth begin to emerge and seem too large or appear to be spaced incorrectly,” Dr. Poole says. “Most children will ‘grow into’ their teeth and go through this phase without the need for orthodontic treatment. But for those children whose teeth protrude significantly, I recommend parents take their child to an orthodontist for an evaluation.”
AAO’s Find an Orthodontist service at www.mylifemysmile.org can locate nearby AAO members. Orthodontists are specialists in the diagnosis, prevention and treatment of patients who have misaligned teeth and/or jaws. After graduating from dental school, prospective orthodontists are required to successfully complete 2-3 additional academic years of study in orthodontics at an accredited orthodontic residency program. Only those with this level of formal education may call themselves “orthodontists.” Only orthodontists are admitted for membership in the AAO.
*Thiruvenkatachari, Badri; Harrison, Jayne; Worthington, Helen; O’Brien, Kevin. “Early orthodontic treatment for Class II malocclusion reduces the chance of incisal trauma: Results of a Cochrane systematic review.” American Journal of Orthodontics & Dentofacial Orthopedics 2015 July; 148:47-59
Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein, Inc. and Steven W. Kess, Vice President of Global Professional Relations, Henry Schein, Inc., were recently honored by the Nassau County Dental Society (NCDS) at its 68th Annual Officers’ Installation Gala held in East Norwich, N.Y.
Henry Schein has supported the Nassau County Dental Society for 14 years through Give Kids A Smile (GKAS), a flagship program of Henry Schein Cares, the company’s global corporate social responsibility program. Since the program’s inception, launched nationally by the American Dental Association in 2003, Henry Schein has been the Professional Products Sponsor. Through this program and Henry Schein’s partnership with NCDS, Give Kids A Smile has helped more than 15,000 Long Island children receive oral health evaluation and treatment.
Photo caption (L to R): Steven W. Kess, Vice President of Global Professional Relations, Henry Schein, Inc.; Jovanna Little, MS, CFRE, PHR, SHRM-CP, Executive Director, Nassau County Dental Society; Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein, Inc.; Michael S. Shreck, DMD, Trustee, New York State Dental Association and Past President, Nassau County Dental Society.
(Charlotte, NC, February 10, 2016) – America’s ToothFairy: National Children’s Oral Health Foundation® and The Salvation Army’s National Headquarters announced a new collaborative initiative to address the issue of pediatric dental disease. Joining efforts to maximize resources and impact on the health of underserved children, this partnership will focus on rescuing children from potentially debilitating, yet preventable, tooth decay through oral health education, awareness building, and expanding access to preventive services and treatment.
The Salvation Army will also participate in the America’s ToothFairy Smile Drive – a national campaign held throughout February, National Children’s Dental Health Month, to collect toothbrushes, toothpaste and other oral care products for underserved children.
“The Salvation Army is committed to addressing the most basic human needs, of which health is one of the most important,” said David Jeffrey, National Commander of The Salvation Army USA. “We look forward to collaborating with America’s ToothFairy to raise awareness of the devastating impact of pediatric dental disease and to ensure the children and families we serve have access to quality, affordable oral health resources and services.”
“We are very proud to partner with The Salvation Army, recognizing their vital contributions to the health and wellness of families across our nation,” said Fern Ingber, America’s ToothFairy President and CEO. “We can think of no better partner in our effort to serve children and families in need.”
Pediatric dental disease is one of the most prevalent illnesses affecting children in the U.S. More than 40 percent of U.S. children have dental cavities by the time they reach kindergarten, and 1 in 5 go without dental care. Left untreated, severe tooth decay can lead to malnourishment, anemia, life-threatening secondary infections and even death.
Dr. Brian Schmidt and Dr. Igor Spigelman will focus on the therapeutic utility of recently developed synthetic cannabinoids, which work to relieve the chronic inflammation and neuropathic pain symptoms of oral cancer without “getting high.”
Chronic pain affects more than 50 million adults in the U.S. Upwards of 9 out of 10 cancer patients suffer from pain, with oral cancer ranked consistently as one of the most painful cancers. This chronic pain management represents a major socioeconomic and clinical challenge because the side effects of existing treatments—mainly prescribing opioids—greatly limit their effectiveness, especially over time.
Alternatives to opioid treatment are found in synthetic and naturally occurring cannabinoids (CBs) which have demonstrated effectiveness in numerous chronic inflammatory and neuropathic disorders in both human and animal models. However, major impediments to the widespread use of CB-based therapies are their psychotropic side-effects, mediated by the activation of central nervous system (CNS) CB1 receptors (CB1Rs).
In other words, cannabis-based drugs work wonders to alleviate chronic pain for patients, but up until now they have come with undesirable psychotropic side effects—patients “get high.”
“We have developed a novel class of drugs, peripherally-restricted cannabinoids (PRCBs), that are free of central nervous system side effects, for treating chronic pain,” said Igor Spigelman, PhD, professor in the Division of Oral Biology & Medicine, UCLA School of Dentistry. Brian L. Schmidt, DDS, MD, PhD professor in the NYU College of Dentistry Department Oral and Maxillofacial Surgery and director of NYU’s Bluestone Center for Clinical Research and the NYU Oral Cancer Center, added: “With this funding, we propose to broaden our research to determine the antitumor potential of PRCBs, their effectiveness against cancer pain, and also against chemotherapy-induced neuropathic pain.”
The purpose of the five-year, $2,494,784 R01 grant from the National Institutes of Health National Cancer Institute (NIH/NCI) is to test PRCBs for oral cancer and chemotherapy-induced peripheral neuropathy pain reduction. To this end, the research team proposes three specific aims for their investigations:
1. To examine the efficacy of novel PRCBs against the chronic pain symptoms of oral cancer. The team hypothesizes that cancer pain can be alleviated by decreasing sensory fiber activation and by reducing tumor burden. Molecular and clinical assays will be used to quantify the anti-proliferative and apoptotic effects of PRCBs. Other experiments will measure the decrement and restoration of orofacial function following PRCB administration. The team will also study the effectiveness of continuous PRCB administration and the possible development of tolerance to the PRCBs for the relief of cancer pain symptoms.
2. To examine the effects of novel PRCBs on proliferation and apoptosis of human oral carcinoma cell lines. Using state-of-the-art sensors which can monitor the reduction in the cancer tumor’s size or rate of growth in real time, the researchers look to measure the dose-response rates of their synthetic cannabinoids being administered.
3. To determine the effectiveness of PRCBs to suppress or prevent the painful symptoms of chemotherapy-induced peripheral neuropathies (CIPNs) without the psychotropic effects of traditional CB treatment. CIPN is a major side effect of chemotherapeutic agents. The researchers have developed their synthetic cannabinoids which have been shown to suppress CIPN symptoms in male rats via CB1R activation, at doses that produce no CNS side effects, and without development of tolerance to daily dosing. Given potential advantages of PRCBs over brain-penetrant cannabinoids, it is important to test if pretreatment with PRCBs can prevent the development of CIPN.
The research team looks to achieve these aims through the use of innovative and validated operant assays which provide a measure of cerebral processing and orofacial function in mouse oral cancer and rat CIPN models. Gender differences in cancer and CIPN pain sensitivity and their responsiveness to PRCBs will be determined. The researchers note, to their knowledge, that no one has studied gender differences in CBR responsiveness in CIPN. Therefore, putative gender differences in responsiveness to PRCBs in CIPN and their causes must be explored. It is also important to establish dose parameters for continued suppression of CIPN symptoms during continuous PRCB administration. The team will also look at whether PRCBs are more or less effective in reducing oral cancer pain in male versus female mice. While oral cancer pain affects men more often than women, it can be profoundly difficult to relieve in both sexes.
“In order to further characterize PRCBs, we plan to perform pharmacokinetic studies and determine their receptor targets with tissue-specific transgenic mice,” said Dr. Schmidt. “We will be looking at how the synthetic cannabinoid moves through and out of the body, charting the time-course of its absorption, bioavailability, distribution within the tissues, and measuring the body’s ability to effectively metabolize the drug.”
In order to measure potential off-target actions and peripheral side effects of PRCBs, the researchers will use a suite of invasive and non-invasive physiological tools, assessing the potential development of tolerance to PRCBs after chronic administration.
“We are keenly interested to determine if pretreatment with PRCBs may actually prevent oral cancer pain and reduced oral cancer proliferation,” said Dr. Schmidt. “Successful completion of the proposed studies would allow us to translate pre-clinical findings to a clinical trial; thus this work would improve outcomes for cancer patients.”
From a public health perspective, the researchers note that, tragically, approximately half of all oral cancer patients will not be cured with surgery, chemotherapy, or radiation therapy. Oral cancer is the sixth most common cancer in the US; however, in certain regions of the world it is the most common cancer. The intensity of oral cancer pain escalates with disease progression, and terminal patients generally experience debilitating pain during their final months of life. Currently, there is little that can be done for these patients. The global burden of oral cancer pain is enormous.
Source: New York University
Miami, FL, Feb. 8 2016 -- MIS Implants, a global leader in implant dentistry, announced today a Mini-Fellowship program in implant dentistry which will be held in conjunction with the University of Miami’s Division of Oral & Maxillofacial Surgery. The program, which will consist of four modules, will be held at the University of Miami’s Miller School of Medicine with faculty from the school’s Division of Oral & Maxillofacial Surgery. The Mini-Fellowship is being sponsored by the Dental Implant Training Center (DITC), a program supported by an unrestricted educational grant from MIS Implants Technologies, Inc.
The program chair, Dr. Michael Peleg, has held various roles in the University Miami School of Medicine including Professor of Clinical Surgery, Residency Program Director, and Fellowship Program Director. Dr. Peleg has designed the mini-fellowship program to allow clinicians with limited Implantology experience to gain an in-depth understanding of the fundamentals of implant dentistry including but not limited to: Anatomy, osseointegration, treatment planning, bone grafting, socket preservation, immediate implant placement, sinus augmentation, prosthodontics, occlusion and biomechanics, aesthetics, guided surgery, and complications in implant dentistry.
The four-module program will be held April 8,9; May 6,7; May 20-21; and June 10-12. All modules will consist of both a didactic portion and hands-on experience. The course will be limited to no more than 15 participants to ensure one on one interaction between the faculty and participants. The Mini-fellowship program is priced at only $5,900, which is a considerable savings from similar programs thanks to MIS’s donation.
“It’s our policy that we do not profit on education so we are able to offerworld class programs such as the University of Miami Mini-Fellowship at a fair price. I am really excited to kick-off this program and to continue our long standing relationship with the faculty at the University of Miami Division of Oral & Maxillofacial Surgery.” - Motti Weisman, MIS Implants USA President and Chairman of the Board
For more details regarding registration for the University of Miami Mini-Fellowship contact the DITC: firstname.lastname@example.org (201) 710-6321
The DITC also offers a comprehensive set of implant dentistry courses out of its New Jersey offices in Fair, Lawn (easily accessible from NY, NJ, CT, and PA.) For a list of current courses visit www.DITCUSA.com.